1. Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH)
- Author
-
Sergio Muntoni, Stefano Bertolini, Livia Pisciotta, and Sandro Muntoni
- Subjects
Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Familial hypercholesterolemia ,PCSK9 Gene ,Endocrinology ,Rosuvastatin Calcium ,Sulfonamides ,Nutrition and Dietetics ,Anticholesteremic Agents ,Homozygote ,Serine Endopeptidases ,Adaptor Proteins ,Single Nucleotide ,Autosomal recessive hypercholesterolemia ,Middle Aged ,Ezetimibe ,NPC1L1 gene ,PCSK9 gene ,Rosuvastatin ,Adaptor Proteins, Signal Transducing ,Apolipoprotein A-I ,Azetidines ,Cholesterol, HDL ,Cholesterol, LDL ,Drug Administration Schedule ,Female ,Fluorobenzenes ,Humans ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Hypercholesterolemia ,Membrane Proteins ,Polymorphism, Single Nucleotide ,Proprotein Convertases ,Pyrimidines ,Treatment Outcome ,Cardiology and Cardiovascular Medicine ,Internal Medicine ,Diabetes and Metabolism ,Cholesterol ,Autosomal Recessive Hypercholesterolemia ,lipids (amino acids, peptides, and proteins) ,Proprotein Convertase 9 ,medicine.drug ,medicine.medical_specialty ,HDL ,LDL ,Internal medicine ,medicine ,Polymorphism ,business.industry ,PCSK9 ,Signal Transducing ,Membrane Transport Proteins ,medicine.disease ,Plasmapheresis ,business - Abstract
Background and aim Previous studies have shown that patients with autosomal recessive hypercholesterolemia (ARH) resulting from mutations in LDLRAP1 gene have a less severe cardiovascular involvement than familial hypercholesterolemia homozygotes, lower levels of low-density lipoprotein cholesterol (LDL-C), and higher levels of high-density lipoprotein cholesterol (HDL-C). In addition, ARH patients seem to be more responsive to the lipid-lowering drugs. The aim was to test the effect of a combined drug treatment in an ARH patient in the absence of plasmapheresis. Methods and results Here we report the lipid-lowering effect of rosuvastatin (60 mg/day) associated with ezetimibe (10 mg/day) in a single ARH patient. The sequencing of LDLRAP1 gene showed that the patient was homozygous for the c.432insA mutation. During a 6-month treatment, we observed an 80% reduction of LDL-C and a significant increase of HDL-C and ApoA-I. Some sequence variations in PCSK9 and NPC1L1 genes found in this patient may have contributed to the success of drug treatment. Conclusions Our findings, although limited to a single case, suggest that in many ARH patients the LDL-C goal may be reached with the more potent statins associated with ezetimibe in the absence of extracorporeal procedures.
- Published
- 2015
- Full Text
- View/download PDF